22 - 24 February, 2011, America Square Conference Centre, London, UK
Free Guest Passes available for qualifying end users - contact us for details on +44(0)20 7368 9300 or email email@example.com
Download the Brochure
Research Article - FlowCytometric Detection of Pig-A Mutant Red Blood Cells Using an Erythroid-Specific Antibody
Evaluation of Macaca mulatta as a model for genotoxicity studies
Nirmala Bhogal, Rita Seabra and Michelle Hudson examine methods to limit the level of animal testing in clinical research
Visit our Download Centre for free downloadable content.
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
Reducing Late Stage Drug Attrition through Predictive Toxicology Approaches in Drug Safety to Maximise Drug Candidate Success and Profitability
'The cost of developing an innovative drug ..... (is) now exceeding the widely quoted figure of US$802 million. Whatever the true cost, however, it is clear that late-stage clinical failures account for a large proportion of the expenses'
As highlighted in the quote above late stage drug attrition accounts for a substantial amount of total development costs. Consequently, there is a strong impetus to improve predictive toxicology technology and assays to forecast toxicity and efficacy of compounds as early as possible in development without stifling the development of potentially safe, profitable drugs.
In light of this, following last year’s success, Pharma IQ is delighted to announce the date for the 3rd Annual Predictive Toxicology Conference which will help you to increase the accuracy of drug safety testing through the integration of advanced prediction methods, including stem cell based assays and screening into your safety evaluation strategy. The main conference will take place in London on 23rd-24th February 2011 and new for this year, there will be a pre-conference focus day on 22nd February 2011 dedicated to the use of stem cells as a tool to enhance predictive toxicology.
In today's pharmaceutical environment two themes predominate, patient safety and probability of technical success. As development of new pharmaceuticals becomes more and more time consuming and expensive, any and all approaches which can identify potential problems must be explored. At the Predictive Toxicology Conference 2010, the aim is to provide attendees with practical knowledge which translates to better patient outcomes and better returns on investment
Late stage attrition of nascent drugs causes substantial losses, both financially and in terms of effort. Conversely, establishing assays with high false positive rates needlessly eliminates compounds that might well have been efficacious and safe in humans. De-risking strategies that predict clinical disposition are the ideal towards which we are moving; we need compounds to fail early, but for the right reasons. Recent advances on several fronts are providing in silico, cellular and animal models that more faithfully predict clinical reality. I am speaking at Predictive Toxicology again this year to help keep attention focused on mitochondrial dysfunction as a key safety issue, but also to hear about the latest developments on other fronts.
Extremely valuable. Gave good overview of trends.
[ Register Now ]
Questions? Contact us on 0800 652 2363 or +44 (0) 20 7368 9300 or email firstname.lastname@example.org now!